oral semaglutide cardiovascular outcomes soul trial results 2024 2025 (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Forecasting Trial Milestones: A Predictive

If side effects become bothersome or severe, healthcare providers may adjust the dosage or consider alternative treatment options

But by emphasizing foods that naturally stimulate greater production of GLP-1, you gain another way to use food to your advantage in optimizing your health

non-enzymatic actions and the overall significance of DPP-4 for normal physiological regulation in humans and for the pathogenesis of metabolic disease are still largely unknown, targeting the catalytic activity has been harnessed pharmacologically, and DPP-4 inhibitors now play an important part in the therapy of T2DM

Ive spoken to many people who are nervous about injections

In some cases, patients may be asked to wear a portable EEG at home for several days to capture activity that doesnt happen regularly